The validation and/or the documentation of test methods was inadequate.
Inspection Record
EverZinc — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The maintenance of detailed plans or specifications was inadequate for each building where drugs are fabricated, packaged, labelled, and/or tested.
The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.
The temperature and/or humidity control was inadequate.
The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.
The investigation, handling, and/or reporting of test results that were out-of-specification was inadequate.
Changes to production processes, systems, equipment, materials, and/or suppliers were not validated before they were implemented. The master formulas to control the manufacturing process were inadequate.
The creation, maintenance, processing, and/or review of laboratory data was inadequate.
About this record
Extracted automatically from the document of the Health Canada inspection on 2023-10-16. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
